Off-the-Shelf cell therapy takes on tough leukemia in early trial
NCT ID NCT07470073
First seen Mar 15, 2026 · Last updated May 08, 2026 · Updated 5 times
Summary
This early-phase study tests a "universal" CAR-T cell therapy (CT1190B) for people aged 12-75 with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The therapy uses donor cells modified to target cancer cells without needing the patient's own cells. The main goals are to check safety, find the best dose, and see how well it works at shrinking the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL (ACUTE B-LYMPHOBLASTIC LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.